English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

The present study describes a subgroup analysis of 33 Japanese patients participating in  UNCOVER ‐1, an international, placebo‐controlled, phase 3 study of ixekizumab in patients with moderate‐to‐severe psoriasis. Patients were randomized to a placebo ( n  = 13) or ixekizumab 80 mg every 4 ( IXEQ 4W,  n  = 12) or 2 ( IXEQ 2W,  n  = 8) weeks, from week 0–12. At week 12, ixekizumab‐treated patients with a static Physician Global Assessment score 0 or 1 ( sPGA  [0,1];  n  = 16) were re‐randomized to a placebo ( n  = 6), ixekizumab 80 mg every 12 ( IXEQ 12W,  n  = 5) or 4 ( IXEQ 4W,  n  = 5) weeks, from week 12–60. At week 12, more ixekizumab‐treated versus placebo‐treated patients achieved  sPGA  (0,1) (≥66.7%  vs  0%), ≥75% improvement in Psoriasis Area and Severity Index (≥75%  vs  0%), and  sPGA  (0) or 100% improvement in Psoriasis Area and Severity Index (both ≥33.3%  vs  0%), with improved symptoms and quality of life. At week 60, 100% ( IXEQ 4W), 40.0% ( IXEQ 12W) and 16.7% (placebo) had maintained  sPGA  (0,1). From week 0–12, treatment‐emergent adverse events were 76.9% (placebo), 75.0% ( IXEQ 4W) and 87.5% ( IXEQ 2W), and from week 12–60 were 66.7% (placebo) and 100% ( IXEQ 12W,  IXEQ 4W). Ixekizumab‐treated patients had no severe treatment‐emergent adverse events, and one serious  TEAE  ( IXEQ 4W); infection was the most frequent treatment‐emergent adverse event. In conclusion, ixekizumab for 60 weeks was effective and safe for Japanese patients with moderate‐to‐severe psoriasis, in line with the overall findings from UNCOVER‐1.

the journal of dermatology

Efficacy and safety of ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis: Subgroup analysis of a placebo‐controlled, phase 3 study (UNCOVER‐1)